A citation-based method for searching scientific literature

Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
Times Cited: 124







List of co-cited articles
894 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
171
41

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.
André J Tremblay, Benoît Lamarche, Carolyn F Deacon, S John Weisnagel, Patrick Couture. Metabolism 2014
82
35

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
27

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
24

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Junichi Matsubara, Seigo Sugiyama, Eiichi Akiyama, Satomi Iwashita, Hirofumi Kurokawa, Keisuke Ohba, Hirofumi Maeda, Koichiro Fujisue, Eiichiro Yamamoto, Koichi Kaikita,[...]. Circ J 2013
141
23

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
23


A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
207
13

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
266
12


The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
Shlomit Koren, Lital Shemesh-Bar, Amit Tirosh, Ronit Koren Peleg, Sylvia Berman, Ramzia Abu Hamad, Shlomo Vinker, Ahuva Golik, Shai Efrati. Diabetes Technol Ther 2012
49
20

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D Margriet Ouwens, Kristin Eckardt, Jean M Kaufman, Mikael Ryden, Stefan Müller,[...]. Diabetes 2011
372
10

Exenatide exerts a potent antiinflammatory effect.
Ajay Chaudhuri, Husam Ghanim, Mehul Vora, Chang Ling Sia, Kelly Korzeniewski, Sandeep Dhindsa, Antoine Makdissi, Paresh Dandona. J Clin Endocrinol Metab 2012
134
10

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Gian Paolo Fadini, Angelo Avogaro. Vascul Pharmacol 2011
158
10

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
Jun Shirakawa, Hideki Fujii, Kei Ohnuma, Koichiro Sato, Yuzuru Ito, Mitsuyo Kaji, Eri Sakamoto, Megumi Koganei, Hajime Sasaki, Yoji Nagashima,[...]. Diabetes 2011
180
9

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
105
9

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Nga N Ta, Corinne A Schuyler, Yanchun Li, Maria F Lopes-Virella, Yan Huang. J Cardiovasc Pharmacol 2011
120
9

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Gian Paolo Fadini, Elisa Boscaro, Mattia Albiero, Lisa Menegazzo, Vera Frison, Saula de Kreutzenberg, Carlo Agostini, Antonio Tiengo, Angelo Avogaro. Diabetes Care 2010
250
9

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
M Barbieri, M R Rizzo, R Marfella, V Boccardi, A Esposito, A Pansini, G Paolisso. Atherosclerosis 2013
103
9

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto,[...]. Diabetes Care 2016
94
9

Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Limei Liu, Jian Liu, Wing Tak Wong, Xiao Yu Tian, Chi Wai Lau, Yi-Xiang Wang, Gang Xu, Yunfei Pu, Zhiming Zhu, Aimin Xu,[...]. Hypertension 2012
134
8

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Liliana Ferreira, Edite Teixeira-de-Lemos, Filipa Pinto, Belmiro Parada, Cristina Mega, Helena Vala, Rui Pinto, Patrícia Garrido, José Sereno, Rosa Fernandes,[...]. Mediators Inflamm 2010
123
8

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Meghan Sauvé, Kiwon Ban, M Abdul Momen, Yu-Qing Zhou, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2010
217
8


Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.
Jitendra Vaghasiya, Navin Sheth, Yagnik Bhalodia, Ravi Manek. Regul Pept 2011
70
11

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Kazufumi Nakamura, Hiroki Oe, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Toru Miyoshi, Kumiko Hirata,[...]. Cardiovasc Diabetol 2014
84
9

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
F Vittone, A Liberman, D Vasic, R Ostertag, M Esser, D Walcher, A Ludwig, N Marx, M Burgmaier. Diabetologia 2012
72
9

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.
Pleun C M van Poppel, Mihai G Netea, Paul Smits, Cees J Tack. Diabetes Care 2011
98
7

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Cristina Mega, Edite Teixeira de Lemos, Helena Vala, Rosa Fernandes, Jorge Oliveira, Filipa Mascarenhas-Melo, Frederico Teixeira, Flávio Reis. Exp Diabetes Res 2011
107
7

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
Goutam C Mistry, Andrea L Maes, Kenneth C Lasseter, Michael J Davies, Keith M Gottesdiener, John A Wagner, Gary A Herman. J Clin Pharmacol 2008
167
7

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Giuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, Ilaria Ferrari, Pietro D Ragonesi, Fabrizio Querci, Ivano G Franzetti, Gennaro Gadaleta, Leonardina Ciccarelli, Mario N Piccinni,[...]. Metabolism 2010
89
7

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Swenja Kröller-Schön, Maike Knorr, Michael Hausding, Matthias Oelze, Alexandra Schuff, Richard Schell, Stephan Sudowe, Alexander Scholz, Steffen Daub, Susanne Karbach,[...]. Cardiovasc Res 2012
128
7

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
Aya Shiraki, Jun-ichi Oyama, Hiroshi Komoda, Machiko Asaka, Aiko Komatsu, Masashi Sakuma, Kazuhisa Kodama, Yoshiko Sakamoto, Norihiko Kotooka, Tetsuaki Hirase,[...]. Atherosclerosis 2012
165
7

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
7


Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Giuseppe Derosa, Anna Carbone, Angela D'Angelo, Fabrizio Querci, Elena Fogari, Arrigo F G Cicero, Pamela Maffioli. Intern Med 2013
22
31

Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
Shinji Ishikawa, Masayuki Shimano, Masato Watarai, Masayoshi Koyasu, Tomohiro Uchikawa, Hideki Ishii, Yasuya Inden, Kenji Takemoto, Toyoaki Murohara. Am J Cardiol 2014
44
15

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.
M Nagashima, T Watanabe, M Terasaki, M Tomoyasu, K Nohtomi, J Kim-Kaneyama, A Miyazaki, T Hirano. Diabetologia 2011
152
7

Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
Carey N Lumeng, Jennifer L Bodzin, Alan R Saltiel. J Clin Invest 2007
7

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
7


DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
Takanori Shinjo, Yusuke Nakatsu, Misaki Iwashita, Tomomi Sano, Hideyuki Sakoda, Hisamitsu Ishihara, Akifumi Kushiyama, Midori Fujishiro, Toshiaki Fukushima, Yoshihiro Tsuchiya,[...]. Am J Physiol Endocrinol Metab 2015
40
17

Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
Dong-Sung Lee, Eun-Sol Lee, Md Morshedul Alam, Jun-Hyeog Jang, Ho-Sub Lee, Hyuncheol Oh, Youn-Chul Kim, Zahid Manzoor, Young-Sang Koh, Dae-Gil Kang,[...]. Metabolism 2016
30
23

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Tomio Onuma, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara,[...]. Diabetes Care 2016
91
7

DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
Fen Zhuge, Yinhua Ni, Mayumi Nagashimada, Naoto Nagata, Liang Xu, Naofumi Mukaida, Shuichi Kaneko, Tsuguhito Ota. Diabetes 2016
93
7

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
Young-Sun Lee, Hee-Sook Jun. Mediators Inflamm 2016
151
7

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
N Matikainen, S Mänttäri, A Schweizer, A Ulvestad, D Mills, B E Dunning, J E Foley, M-R Taskinen. Diabetologia 2006
246
6

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Yumei Ye, Kyle T Keyes, Congfang Zhang, Jose R Perez-Polo, Yu Lin, Yochai Birnbaum. Am J Physiol Heart Circ Physiol 2010
127
6

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.
Bruna Pm Pacheco, Renato O Crajoinas, Gisele K Couto, Ana Paula C Davel, Lucília M Lessa, Luciana V Rossoni, Adriana Cc Girardi. J Hypertens 2011
95
6

Cardiovascular effects of gliptins.
André J Scheen. Nat Rev Cardiol 2013
116
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.